Global Blood Therapeutics Inc.

09/07/2021 | Press release | Distributed by Public on 09/07/2021 06:12

U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11